Literature DB >> 12753172

Expression of neurotrophin receptor Trk-C in nevi and melanomas.

Xiaowei Xu1, Steven R Tahan, Terri L Pasha, Paul J Zhang.   

Abstract

BACKGROUND: Neurotrophins (NTs) are growth factors for neurons and other neural crest-derived cells. Their functions are mediated by 75-kDa low-affinity glycoprotein receptor (p75) NT receptor and a family of tyrosine kinase receptors (Trks) that includes Trk-A, -B, and -C. Signal transduction through the Trk receptors has been shown to regulate growth and apoptosis of tumors of neuronal origin. In addition, Trk oncogenes have been shown to be rearranged in some non-neuronal neoplasms. Recently, immunoexpression of NT-3 has been shown to be significantly higher in melanomas than in banal nevi on cryostat tissue.
METHODS: Since the biologic function of NT-3 is mediated primarily through Trk-C, we investigated Trk-C immunoexpression on paraffin sections of 10 compound nevi and 63 melanomas.
RESULTS: The expression of Trk-C was relatively low in compound nevi (30%). Trk-C expression was overall 62% in melanomas of various stages. Our data show that the expression of Trk-C increased as melanoma progressed from in situ (58%) to papillary dermal invasion (91%), and then declined in deeper (57%) and metastatic melanomas (31%).
CONCLUSION: These findings suggest a possible role of Trk-C in the progression of early stages of melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753172     DOI: 10.1034/j.1600-0560.2003.00068.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  15 in total

1.  Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.

Authors:  Mahalakshmi Palani; R Arunkumar; Arrambakam Janardhanam Vanisree
Journal:  Neuromolecular Med       Date:  2014-05-20       Impact factor: 3.843

Review 2.  Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression.

Authors:  Tura C Camilli; Ashani T Weeraratna
Journal:  Biochem Pharmacol       Date:  2010-03-06       Impact factor: 5.858

3.  Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker.

Authors:  Shahin Behrouz Sharif; Shahriar Hashemzadeh; Reza Mousavi Ardehaie; Amirtaher Eftekharsadat; Mortaza Ghojazadeh; Amir Hossein Mehrtash; Mehrdad Asghari Estiar; Ladan Teimoori-Toolabi; Ebrahim Sakhinia
Journal:  Oncol Lett       Date:  2016-10-31       Impact factor: 2.967

4.  TrkC-Targeted Kinase Inhibitors And PROTACs.

Authors:  Bosheng Zhao; Kevin Burgess
Journal:  Mol Pharm       Date:  2019-09-12       Impact factor: 4.939

5.  Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis.

Authors:  Jimena Bouzas-Rodriguez; Jorge Ruben Cabrera; Céline Delloye-Bourgeois; Gabriel Ichim; Jean-Guy Delcros; Marie-Anne Raquin; Raphaël Rousseau; Valérie Combaret; Jean Bénard; Servane Tauszig-Delamasure; Patrick Mehlen
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

6.  Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Authors:  Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

Review 7.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

8.  Double-targeting using a TrkC ligand conjugated to dipyrrometheneboron difluoride (BODIPY) based photodynamic therapy (PDT) agent.

Authors:  Anyanee Kamkaew; Kevin Burgess
Journal:  J Med Chem       Date:  2013-09-24       Impact factor: 7.446

9.  An agent for optical imaging of TrkC-expressing, breast cancer.

Authors:  Anyanee Kamkaew; Feng Li; Zheng Li; Kevin Burgess
Journal:  Medchemcomm       Date:  2017-09-14       Impact factor: 3.597

10.  NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer.

Authors:  Yanxin Luo; Andrew M Kaz; Samornmas Kanngurn; Piri Welsch; Shelli M Morris; Jianping Wang; James D Lutterbaugh; Sanford D Markowitz; William M Grady
Journal:  PLoS Genet       Date:  2013-07-11       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.